Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
France
/
Pharmaceuticals & Biotech
Create a narrative
Valneva Community
ENXTPA:VLA Community
1
Narratives
written by author
0
Comments
on narratives written by author
17
Fair Values set
on narratives written by author
Create a narrative
Valneva
Popular
Undervalued
Overvalued
Community Investing Ideas
Valneva
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Upcoming Lyme Vaccine Data Will Unlock Market Opportunities
Key Takeaways Potential success of the Lyme disease vaccine could significantly boost future revenue and earnings through strategic regulatory filings and commercialization milestones. Strategic operational improvements, such as reducing cash burn and enhancing gross margins, aim to improve midterm profitability and net margins.
View narrative
€6.61
FV
56.6% undervalued
intrinsic discount
19.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
3 days ago
author updated this narrative
Your Valuation for
VLA
VLA
Valneva
Your Fair Value
€
Current Price
€2.87
37.7% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-135m
428m
2015
2018
2021
2024
2025
2027
2030
Revenue €427.8m
Earnings €84.5m
Advanced
Set Fair Value